Treatment by international prognostic scoring system risk group

Most treatment options that currently are EMA approved for MDS have been evaluated in clinical trials enrolling patients based on their risk status according to IPSS.

The ELN MDS guidelines that were published 2013 (Malcovati, et al, Blood 2013) used IPSS as basis for the decision model